Genetic markers for predicting responsiveness to fgf-18 compound
AssigneeMerck Patent GmbH
InventorsChristoph Hubertus Ladel, Alix Anne Simone Berton, Armand Valsesia, Pierre Jacques Farmer
Life of this patent
Estimating the term…
Abstract
This application is directed to the use of biomarkers for predicting the sensitivity to treatment with an FGF-18 compound of a patient having a cartilage disorder, such as osteoarthritis, cartilage injury, fractures affecting joint cartilage or surgical procedures with impact on joint cartilage (e.g., microfracture), in order to reduce the risk of adverse events and increase the overall benefit after therapy.
Claims7
A kit comprising means for performing the method according to claim 19 and instructions for use.
A method for treating a patient having a cartilage disorder, comprising the following steps:
- a) determining, from a nucleic acid sample, the genotype at both IL-1RN rs9005 and IL-1RN rs315952;
- b) selecting the patient having any combination of the genotype(s) selected from the group consisting of:
- i) G/G at IL-1RN rs9005 and T/C or C/C at IL-1RN rs315952;
- or
- ii) A/G or A/A at IL-1RN rs9005 and T/T, T/C or C/C at IL-1RN rs315952;
- and
- c) administering intraarticularly an FGF-18 compound to said selected patient.
Dependencies are inferred from the claim text.